Image Source: AsiaOne
Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in ChinaGlobeNewswireJuly 13, 2020SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today the completion of study subjects enrollment in Phase I trial of SARS-CoV-2 neutralizing monoclonal antibody injection (Product Code: JS016), developed jointly with Institute of Microbiology, Chinese Academy of Sciences (IMCAS). JS016 is the first COVID-19 neutralizing antibody entering clinical trials in China. It also entered in clinical trials in the US during the second quarter.
Source: AsiaOne